

World Journal of *Gastroenterology*

World J Gastroenterol 2017 June 21; 23(23): 4135-4316



**EDITORIAL**

- 4135** Attenuated adenomatous polyposis of the large bowel: Present and future
Roncucci L, Pedroni M, Mariani F
- 4140** Evolution of associating liver partition and portal vein ligation for staged hepatectomy: Simpler, safer and equally effective methods
Peng SY, Wang XA, Huang CY, Zhang YY, Li JT, Hong DF, Cai XJ

REVIEW

- 4146** Antioxidant dietary approach in treatment of fatty liver: New insights and updates
Ferramosca A, Di Giacomo M, Zara V
- 4158** *Helicobacter pylori* BabA in adaptation for gastric colonization
Ansari S, Yamaoka Y

MINIREVIEWS

- 4170** Advances in surgical management for locally recurrent rectal cancer: How far have we come?
Lee DJK, Sagar PM, Sadadcharam G, Tan KY

ORIGINAL ARTICLE**Basic Study**

- 4181** Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease
Paka L, Smith DE, Jung D, McCormack S, Zhou P, Duan B, Li JS, Shi J, Hao YJ, Jiang K, Yamin M, Goldberg ID, Narayan P
- 4191** Induction of chronic cholestasis without liver cirrhosis - Creation of an animal model
Dondorf F, Fahrner R, Ardelt M, Patsenker E, Stickel F, Dahmen U, Settmacher U, Rauchfuß F
- 4200** Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an *in vivo* model
Dianzani C, Foglietta F, Ferrara B, Rosa AC, Muntoni E, Gasco P, Della Pepa C, Canaparo R, Serpe L
- 4211** Relevance of proteolysis and proteasome activation in fatty liver graft preservation: An Institut Georges Lopez-1 vs University of Wisconsin appraisal
Zaouali MA, Panisello-Roselló A, Lopez A, Castro Benítez C, Folch-Puy E, García-Gil A, Carbonell T, Adam R, Roselló-Catafau J

- 4222** Naturally occurring mutations in the reverse transcriptase region of hepatitis B virus polymerase from treatment-naïve Korean patients infected with genotype C2

Kim JE, Lee SY, Kim H, Kim KJ, Choe WH, Kim BJ

- 4233** Inhibition of N-methyl-N-nitrosourea-induced gastric tumorigenesis by Liuwei Dihuang Pill in db/db mice

Zhuang S, Jian YM, Sun YN

- 4243** miR-382 functions as a tumor suppressor against esophageal squamous cell carcinoma

Feng J, Qi B, Guo L, Chen LY, Wei XF, Liu YZ, Zhao BS

Case Control Study

- 4252** Pancreas preserving distal duodenectomy: A versatile operation for a range of infra-papillary pathologies

Mitchell WK, Thomas PF, Zaitoun AM, Brooks AJ, Lobo DN

Retrospective Study

- 4262** Clinical importance of colonoscopy in patients with gastric neoplasm undergoing endoscopic submucosal dissection

Tsuchida C, Yoshitake N, Kino H, Kaneko Y, Nakano M, Tsuchida K, Tominaga K, Sasai T, Masuyama H, Yamagishi H, Imai Y, Hiraishi H

- 4270** Outcomes of right-lobe and left-lobe living-donor liver transplantations using small-for-size grafts

She WH, Chok KSH, Fung JYY, Chan ACY, Lo CM

Clinical Trials Study

- 4278** Potential application of neogalactosylalbumin in positron emission tomography evaluation of liver function

Du SD, Li SH, Jin B, Zhu ZH, Dang YH, Xing HQ, Li F, Wang XB, Lu X, Sang XT, Yang HY, Zhong SX, Mao YL

Observational Study

- 4285** Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease

Thomassin L, Armengol-Debeir L, Charpentier C, Bridoux V, Koning E, Savoye G, Savoye-Collet C

- 4293** New totally intracorporeal reconstructive approach after robotic total gastrectomy: Technical details and short-term outcomes

Parisi A, Ricci F, Gemini A, Trastulli S, Cirocchi R, Palazzini G, D'Andrea V, Desiderio J

EVIDENCE-BASED MEDICINE

- 4303** Substantial hepatic necrosis is prognostic in fulminant liver failure

Ndekwe P, Ghabril MS, Zang Y, Mann SA, Cummings OW, Lin J

CASE REPORT

- 4311** Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a *PIK3CA* mutation

Bian JL, Wang MM, Tong EJ, Sun J, Li M, Miao ZB, Li YL, Zhu BH, Xu JJ

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Akira Hokama, MD, PhD, Professor, Department of Endoscopy, University of the Ryukyus, Nishihara, Okinawa 903-0215, Japan

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central and Directory of Open Access Journals. The 2017 edition of Journal Citation Reports[®] released by Clarivate Analytics (Former Thomson Reuters) cites the 2016 impact factor for *WJG* as 3.365 (5-year impact factor: 3.176), ranking *WJG* as 29th among 79 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Fen-Fen Zhang*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Ze-Mao Gong*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE
Jin-Lei Wang, Director
Yuan Qi, Vice Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE
June 21, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Substantial hepatic necrosis is prognostic in fulminant liver failure

Paul Ndekwe, Marwan S Ghabril, Yong Zang, Steven A Mann, Oscar W Cummings, Jingmei Lin

Paul Ndekwe, Steven A Mann, Oscar W Cummings, Jingmei Lin, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, United States

Marwan S Ghabril, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, IN 46202, United States

Yong Zang, Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN 46202, United States

Author contributions: Ndekwe P and Lin J designed research/study; Ndekwe P, Ghabril MS, Mann SA and Lin J performed research/study and collected data; Ndekwe P, Ghabril MS, Zang Y, Mann SA, Cummings OW and Lin J analyzed data; Ndekwe P, Ghabril MS, Mann SA, Cummings OW and Lin J wrote paper.

Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of Indiana University School of Medicine.

Conflict-of-interest statement: The authors have no conflicts of interest to disclose.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Invited manuscript

Correspondence to: Jingmei Lin, MD, PhD, Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 350 West 11th Street, Indianapolis, IN 46202, United States. jinglin@iupui.edu
Telephone: +1-317-4916159

Fax: +1-317-4916419

Received: October 6, 2016

Peer-review started: October 10, 2016

First decision: December 19, 2016

Revised: March 21, 2017

Accepted: May 19, 2017

Article in press: May 19, 2017

Published online: June 21, 2017

Abstract

AIM

To evaluate if any association existed between the extent of hepatic necrosis in initial liver biopsies and patient survival.

METHODS

Thirty-seven patients with fulminant liver failure, whose liver biopsy exhibited substantial necrosis, were identified and included in the study. The histological and clinical data was then analyzed in order to assess the relationship between the extent of necrosis and patient survival, with and without liver transplantation. The patients were grouped based on the etiology of hepatic necrosis. Each of the etiology groups were then further stratified according to whether or not they had received a liver transplant post-index biopsy, and whether or not the patient survived.

RESULTS

The core tissue length ranged from 5 to 44 mm with an average of 23 mm. Causes of necrosis included 14 autoimmune hepatitis, 10 drug induced liver injury (DILI), 9 hepatitis virus infection, and 4 unknown origin. Among them, 11 showed submassive (26%-75% of the parenchymal volume) and 26 massive (76%-100%) necrosis. Transplant-free survival was worse in patients with a higher extent of necrosis (40%, 71.4% and 100% in groups with necrosis of 76%-100%, 51%-75%

and 26%-50%, respectively). Additionally, transplant-free survival rates were 66.7%, 57.1%, and 25.0% in groups of autoimmune hepatitis, DILI, and viral hepatitis, respectively. Even after liver transplantation, the survival rate in patients as a result of viral hepatitis remained the lowest (80%, 100%, and 40% in groups of autoimmune hepatitis, DILI, and viral hepatitis, respectively).

CONCLUSION

Adequate liver biopsy with more than 75% necrosis is associated with significant transplant-free mortality that is critical in predicting survival.

Key words: Submassive necrosis; Massive necrosis; Fulminant liver failure; Liver transplantation; Biopsy; Histopathology

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Fulminant liver failure is clinically characterized by an abrupt onset of jaundice and liver dysfunction with subsequent development of encephalopathy and coagulopathy in patients with or without preexisting liver disease. Liver biopsy may play a role in predicting patient survival, and may also potentially play a role in optimizing the utilization of resources in the setting of fulminant liver failure.

Ndekwe P, Ghabril MS, Zang Y, Mann SA, Cummings OW, Lin J. Substantial hepatic necrosis is prognostic in fulminant liver failure. *World J Gastroenterol* 2017; 23(23): 4303-4310 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i23/4303.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i23.4303>

INTRODUCTION

Fulminant liver failure is clinically characterized by an abrupt onset of jaundice and liver dysfunction with subsequent development of encephalopathy and coagulopathy in patients with or without preexisting liver disease^[1-6]. Common etiologies for fulminant liver failure include viral hepatitis, autoimmune hepatitis, and drug induced liver injury (DILI)^[7,8]. Other precipitating events comprise alcoholic liver disease, ischemia, portal vein thrombosis, and infection^[9-11]. In some cases, a precipitating factor is never identified^[9-11]. Regardless of the etiology, fulminant liver failure is typically associated with high morbidity and mortality^[1]. In the clinical setting, the grade of encephalopathy has a strong association with prognosis^[12]. Other prognostic indicators encompass coagulation factors (INR or Factor V levels), serum bilirubin, transaminases, creatinine, arterial pH, and serum lactate^[12]. Additionally, computed tomographic

assessment of liver atrophy is said to be of prognostic value^[13]. As such, multiple prognostic models (e.g., Clichy, King's College), based mainly on laboratory values and clinical findings, have been used to rapidly assess the need for transplantation^[4,9-12].

Liver biopsy is the gold standard for evaluating hepatic diseases. However, these fulminant liver failure models do not directly taken into account the histopathological findings obtained *via* liver biopsy. Submassive or massive liver necrosis is the worst histological finding that is seen in association with fulminant liver failure, although it is not seen in every biopsy. In fulminant liver failure, the prognosis for those with significant hepatic necrosis is generally thought to be poor. And yet, the extent of necrosis in a biopsy, and its importance in predicting patient outcomes, is less well defined in the literature^[7,14]. One study even casts doubt on the value of hepatic necrosis as a prognostic indicator^[7].

In this study, we aimed to evaluate if there is any association between the degree of hepatocellular necrosis and patient survival. Additionally, we attempted to identify any relationship between the underlying etiology of necrosis and survival. Lastly, we evaluated the outcomes of liver transplantation following a histopathological diagnosis of significant hepatic necrosis.

MATERIALS AND METHODS

Patients and histology

A search of our institution's pathology database was performed in order to retrospectively identify native liver biopsies with a diagnosis of either submassive or massive hepatic necrosis. Thirty-seven liver biopsies, originally performed from 2004 to 2013, were identified. The biopsies were distributed among 37 individual patients who were clinically diagnosed with fulminant liver failure. Hepatic necrosis is defined as death of hepatocytes, which maybe single cell, multiple cells in piecemeal, focal, multifocal, submassive or massive (Figure 1). Submassive hepatic necrosis is defined as necrosis involving 26%-75% of the parenchymal volume, while massive necrosis involves more than 75%. The percentage of hepatic necrosis is determined based on the total amount of necrotic hepatic tissue present vs the amount of total parenchyma. Hematoxylin and eosin (H&E) slides for each of the individual biopsies were reviewed by an experienced pathologist (Lin J) to assess the percentage of necrosis and other pathologic features.

A review of each individual patient's electronic medical chart was performed and relevant clinical data was obtained. Collected data included age, gender, etiology of hepatic necrosis, presence of hepatic encephalopathy, whether or not the patient received treatment related to the underlying disease, whether or not liver transplantation was performed after the index liver biopsy, and survival time. Additional clinical




Figure 1 Mass and submassive liver necrosis. A: Low power magnification showing complete hepatocellular necrosis in a core biopsy ($\times 40$); B: Medium power magnification showing a liver biopsy with perivenular predominant hepatocellular necrosis and intermixed viable hepatocytes located around the portal tract ($\times 40$); C: High magnification of image A showing hepatocellular necrosis and profound inflammatory infiltrate in which the architecture of hepatocyte is preserved ($\times 200$); D: High magnification of image B reveals the collapse of parenchyma that is replaced by necroinflammatory infiltrate in comparison to the adjacent viable hepatocytes in the right upper corner ($\times 200$).

information included patient INR values, presence of a bacterial infection, and whether or not ascites was present.

The histological and clinical data was then analyzed in order to assess the relationship between the extent of necrosis and patient survival, with or without liver transplantation. Patients were sorted into three groups based on the percentage of necrosis present within the biopsy (26%-50%, 51%-75%, and 76%-100%). Each of the three percentage groups was then further stratified according to whether or not they had subsequently received a liver transplant.

A separate analysis of all data was then performed in order to assess the relationship between the etiology of hepatic necrosis and patient prognosis, with or without liver transplantation. The patients were grouped based on etiology of hepatic necrosis. Etiologies included autoimmune hepatitis, DILI, viral hepatitis, and unknown. An unknown etiology was defined as any case in which there was no clearly identified cause following an extensive clinical workup. Each of the etiology groups were then further stratified according to whether or not they had received a liver transplant post-index biopsy, and whether or not the patient survived.

Statistical analysis

Statistical analysis methodologies included Fisher's exact test and χ^2 test. *P* values of < 0.05 were considered

statistically significant. All statistics were performed by an experienced statistician (Zang Y).

RESULTS

Patients and liver biopsies

The patients within the study ranged in age from 18 to 75 years old with a mean age of 41 years. Two patients were less than 20 years old; 10 were in the 21-30 year old age group, 4 in the 31-40 age group, 7 in the 41-50 age group, 6 in the 51-60 age group, 5 in the 61-70 age group, and 3 patients were older than 70. Fourteen (37.8%) were male and 23 (62.2%) were female.

Tissue adequacy for pathologic assessment was evaluated. Of 37 liver biopsies, the core tissue length ranged from 5 mm to 44 mm with an average of 23 mm. Twenty-three biopsies (62%) were in the length of > 20 mm, 11 (30%) in the range of 10-20 mm, and 3 (8%) < 10 mm.

Causes of submassive or massive liver necrosis included autoimmune hepatitis in 14 patients, DILI in 10 (9 due to acetaminophen and 1 due to clopidogrel), hepatitis virus infection in 9 patients (1 hepatitis A, 5 hepatitis B, 2 hepatitis C, and 1 with both hepatitis B and C), and unknown origin in 4. All patients within the study underwent biopsy with a clinical diagnosis of fulminant liver failure. Survival times for all 37 patients ranged from less than 1 mo to 127 mo according to

Table 1 Clinical features of the patients who had submassive or massive hepatic necrosis *n* (%)

Extent of necrosis	Patients (<i>n</i> = 37)	Ascites	Bacterial infection	INR mean and range
26%-50%	1	0 (0)	0 (0)	1.34 (1.34)
51%-75%	10	1 (10)	0 (0)	2.19 (0.95-4.52)
76%-100%	26	5 (19.2)	3 (11.5)	2.64 (1.10-5.91)

The INR data were not available for one patient in the 51%-75% and 76%-100% groups, respectively.

the last visit record for each patient. The mean survival time was 41 mo.

Ascites, INR, bacterial infection, and hepatic necrosis

As shown in Table 1, the single patient with 26%-50% necrosis had an INR of 1.34, and no clinical evidence of bacterial infection or ascites. Only 1 of the 10 patients with 51%-75% necrosis had ascites. The mean INR for the patients within this group was 2.19, with individual values ranging from 0.95 to 4.52. None of the patients within this group had evidence of a bacterial infection. Three of the 26 patients with 76%-100% hepatic necrosis had a bacterial infection. The mean INR for patients in this group was 2.64, with individual values ranging from 1.10-5.91. Five of these patients had ascites.

Statistical analysis using Fisher exact test demonstrated that there was no significant association between the presence of ascites and extent of necrosis ($P = 0.71$). Additionally, Fisher's exact test showed no significant association between the presence of bacterial infection and extent of necrosis ($P = 0.58$). Analysis of variance showed that there was no significant association between mean INR level and extent of necrosis ($P = 0.45$).

Outcome of percentage of hepatic necrosis with respect to survival

As shown in Table 2, one patient had 26%-50% hepatic necrosis at the time of biopsy. Ten patients had 51%-75% and 26 patients had 76%-100% necrosis. No bridging fibrosis or cirrhosis was appreciated in any of them. The patient within the 26%-50% group did not receive a transplant and is currently still living well with a followup of 86 mo. Out of the 10 patients with 51%-75% necrosis, 3 received a liver transplant and are still alive (100%) with a mean followup of 86 mo (range, 66-103 mo). Within this group, 5 of the 7 who did not receive a transplant are currently still living (71.4%) with a mean followup of 72 mo (range, 21-127 mo) and 2 died (both < 1 mo after the index liver biopsy). Within the 76%-100% necrosis group, 11 underwent liver transplantation; of these, 7 are still alive (63.6%) and 4 died. Of the 15 transplant-free patients within this group, 6 survived (40%) with a mean followup of 65 mo (range, 28-122 mo) and

9 died (mean, 3 mo; range, 1-14 mo after the index biopsy).

In summary, transplant-free survival appeared worse in patients with a higher extent of necrosis (40%, 71.4% and 100% in groups with necrosis of 76%-100%, 51%-75% and 26%-50%, respectively). Although higher-extent hepatic necrosis appeared to be associated with worse prognosis, statistically there was no significance between the submassive and the massive necrosis groups ($P > 0.05$).

Liver transplantation improved patient survival. The patients who received liver transplantation appeared to have somewhat better survival rates compared with non-transplanted patients (100% vs 71.4% and 63.6% vs 40.0% in 51%-75% and 76%-100% necrosis groups, respectively). However, statistical analysis using Fisher's exact test showed no significant difference in the survival rates of patients within the transplanted and non-transplanted groups, probably due to a small sample size.

Outcome of etiologies causing substantial necrosis respective to survival

Further analysis based upon the etiology of substantial hepatic necrosis, transplantation status, and survival was shown in Table 3. For the 10 cases of drug induced hepatic necrosis, only 3 were transplanted and all of them survived (100%). Four of the 7 who did not receive a transplant survived (57.1%). Overall survival rates for DILI group were not statistically different, depending on transplantation status ($P = 0.475$).

Of the 14 cases due to autoimmune hepatitis, 5 underwent liver transplantation and 4 patients survived (80.0%). Six of the 9 patients with autoimmune hepatitis who did not receive transplant survived (66.7%). Overall survival rates were not significantly different, depending on transplantation status ($P = 1$).

Five patients within the viral hepatitis group underwent transplantation and only 2 survived (40.0%). In comparison, only 1 of the 4 viral hepatitis patients survived without transplantation (25.0%). Although the overall survival rate was higher in the transplant group, there was no statistical significance ($P = 1$).

For the 4 cases of unknown hepatic necrosis, only 1 patient was transplanted. This patient survived. One of the 3 who did not receive a transplant survived. Overall survival rates for the unknown group with or without transplantation were 100% and 33.3%, respectively. Although transplant group had higher survival rate, there was no statistical significance ($P = 1$).

In summary, transplant-free survival rates were 66.7%, 57.1%, and 25.0% in groups of autoimmune hepatitis, DILI, and viral hepatitis, respectively. Although the survival rates appeared different among the various etiology groups, a statistically significant difference only existed between autoimmune hepatitis and viral hepatitis groups ($P = 0.048$). Even after

Table 2 Prognosis of the patients who had submassive or massive hepatic necrosis with respect to liver transplantation *n* (%)

Extent of necrosis	Patients (<i>n</i> = 37)	Received transplant (<i>n</i> = 14)		Transplant free (<i>n</i> = 23)	
		Died	Survived	Died	Survived
26%-50%	1	NA	NA	NA	1 (100)
51%-75%	10	NA	3 (100)	2 (28.6)	5 (71.4)
76%-100%	26	4 (36.4)	7 (63.6)	9 (60.0)	6 (40.0)

NA: Not applicable.

Table 3 Prognosis of the patients who had submassive or massive hepatic necrosis with respect to the etiology *n* (%)

Etiology	Patients (<i>n</i> = 37)	Received transplant (<i>n</i> = 14)		Transplant free (<i>n</i> = 23)	
		Died	Survived	Died	Survived
DILI	10	NA	3 (100)	3 (42.9)	4 (57.1)
AIH	14	1 (20.0)	4 (80.0)	3 (33.3)	6 (66.7)
Viral hepatitis	9	3 (60.0)	2 (40.0)	3 (75.0)	1 (25.0)
Unknown	4	NA	1 (100)	2 (66.7)	1 (33.3)

NA: Not applicable; AIH: Autoimmune hepatitis; DILI: Drug induced liver injury.

Table 4 Hepatic encephalopathy with respect to the extent of hepatic necrosis *n* (%)

Extent of necrosis	Patient number (<i>n</i> = 37)	Encephalopathy	
		Present (<i>n</i> = 5)	Absent (<i>n</i> = 32)
26%-50%	1	0	1 (100)
51%-75%	10	0	10 (100)
76%-100%	26	5 (19.2)	21 (80.8)

liver transplantation, the survival rate in patients as a result of viral hepatitis remained the lowest when compared with the other groups, although no statistical significance has been reached between DILI and viral hepatitis ($P = 0.058$ or 0.090), or between DILI and autoimmune hepatitis ($P = 0.116$ or 0.408) in the setting of transplant or transplant-free, respectively.

Correlation between hepatic encephalopathy, extent of necrosis, transplant and survival

As demonstrated in Table 4, the patient within 26%-50% necrosis group did not have encephalopathy; nor did any of the patients within 51%-75% group. Five patients within 76%-100% group had encephalopathy (19.2%). Thus, it appears that a higher extent of liver necrosis is possibly associated with encephalopathy. Further analysis of the patients who had encephalopathy revealed that the sole surviving patient (10%) within this group underwent liver transplantation, with a followup time of 92 mo. This finding was statistically significant when compared to the transplant-free group (57.1%, $P < 0.05$).

Of the 21 patients in 76%-100% necrosis group without encephalopathy, 10 underwent transplantation, and the survival rate was statistically significant (60.0%) when compared to the survival rate of 54.5% in those who did not undergo transplantation ($P < 0.05$). Encephalopathy is an important prognostic

predictor. The survival rate for transplant-free patients with encephalopathy was much lower compared with the group without encephalopathy (0% vs 54.5%; $P < 0.05$).

DISCUSSION

Studies addressing the prognostic value of liver biopsies with substantial necrosis are rare, and the conclusions are not well defined in the literature^[14,15]. Hanau and colleagues questioned the value of hepatic necrosis in predicting clinical outcome, because about 50% of the biopsies in their study showed minimal bridging necrosis^[7]. In their 1995 study, patients were selected based solely on their clinical characteristics (e.g., signs and symptoms of fulminant liver failure with elevated liver function tests). In contrast, we selected and stratified our study cohorts based on the extent of necrosis in the liver biopsies. Although Hanau's study included 38 cases, only 12 liver biopsies demonstrated either $> 90\%$ (3) or $10\%-90\%$ (9) necrosis. Additionally, Hanau and colleagues found that only one of seven (14.3%) patients whose liver biopsy demonstrated $\geq 70\%$ necrosis survived without transplantation, keeping in line with our finding. In another study in 1993, Donaldson and colleagues found that only 2 of 19 patients (10.5%) with $> 70\%$ necrosis survived without transplantation^[14]. These findings indicate that the percentage of hepatic necrosis may be an important prognosticator for patient survival. As noted, our transplant-free survival rates are much higher with 71.4% and 40% for 51%-75% and $> 75\%$ necrosis, respectively. A possible explanation for the difference in transplant-free survival might be related to the different therapeutic options utilized in the respective study cohorts. It seems likely that some more effective non-transplant related treatments

were available for the patients in our study; as the two aforementioned studies took place more than two decades ago. Since then, it appears that no report has been added in the literature in the regard of prognostic value of liver biopsy in an advantaged era of liver transplantation for the past 20 years. To the best of our knowledge, our study is the largest ever to address whether or not there is an association between substantial hepatic necrosis and prognosis (11 with 26%-75% and 26 with > 75% necrosis)^[7,14]. Despite a difference in approaches between our study, the Donaldson study, and the Hanau study, a similar trend seems to be present; as the degree of hepatic necrosis increases, the transplant-free survival rate declines. However, the statistical significance of this trend is still not readily apparent, and more studies are certainly warranted.

Adequacy is an important matter to consider, given the well-known fact that necrosis is often heterogeneously distributed throughout the liver^[7]. The mean core tissue length of 23 mm in our study and 21 mm in Donaldson's^[14] study are both adequate. Specimen adequacy is not mentioned in Hanau's study^[7]. Inadequate biopsy specimens, localized liver necrosis^[7], and a prolonged interval between the time of symptoms and biopsy, are the most common causes of a discrepancy between the extent of necrosis in a liver biopsy when compared to hepatectomy specimens from the same patient (our unpublished data). Therefore, if a liver biopsy is going to be obtained, it is best obtained from a patient where diffuse hepatic necrosis is suspected; provided that the biopsy will be adequate and is taken as soon as possible following the onset of symptoms. Localized liver necrosis due to ischemia or other injury can be feasibly monitored by CT/MRI imaging, and the interpretation of the biopsy should be considered as a local event.

Importantly, our study has indicated that there may be association between etiology and patient survival in the setting of submassive or massive necrosis, which has not been discussed in the prior reports^[7,14,15]. In our study, survival was the worst in those with hepatotropic viral hepatitis as the underlying etiology, regardless of the status of liver transplantation. Patients with autoimmune hepatitis induced hepatic necrosis had the best transplant-free survival and those with DILI had the best survival after transplantation. It is not entirely clear why different causes may lead to different survival from our study. One might speculate that differences in patient age, availability of effective therapeutic options, or preexisting co-morbidities might play a role in prognosis. In our study, the median age for those with massive hepatic necrosis was 49, 43, 48, and 44 years in autoimmune hepatitis, DILI, viral hepatitis, and unknown groups, respectively (Supplement 1). This finding demonstrates a lack of correlation between age and prognosis in the setting of substantial hepatic necrosis, although age has been

suggested as playing a role in Hanau's study^[7]. In our study, the autoimmune hepatitis group had the greatest median age, and yet had the best overall survival. It is likely that effective therapeutic agents in autoimmune hepatitis might play a role in explaining why transplant-free survival is better when compared with other etiologies. However, due to the small number of cases in each of the substratified groups, no definitive conclusions can be drawn and further investigation seems warranted.

Bacterial infections and ascites were present more frequently in patients with a higher extent of hepatic necrosis. Mean INR for the patients with higher percentages of hepatic necrosis were also higher than in patients with a smaller percentage of necrosis. However none of these trends were found to be statistically significant. It is likely that a larger study may be able to identify a statistically significant association between these individual parameters.

Hepatic encephalopathy is present more frequently in the patients with massive necrosis. However, the incidence seems low in our study (19.2%). The relatively low incidence of encephalopathy might reflect the characteristics of the study cohort in our institution. The lack of a clear statistically significant association between extent of necrosis and encephalopathy is likely due to the relatively low number of patients in our study. In patients with hepatic encephalopathy and massive necrosis, the prognosis is extremely miserable. The only patient with encephalopathy who survived received a liver transplant. This finding suggests that encephalopathy due to hepatic necrosis may be associated with increased mortality. It also suggests that liver transplantation may be useful in this setting^[16-20].

In conclusion, accurate histopathological evaluation in patients with fulminant liver failure is useful. However, more research with a larger number of patients is required to truly identify any significant associations between the extent of hepatic necrosis and prognosis. The significance of liver biopsy is not limited to identifying or confirming the etiology; it is also a valuable tool in the assessment of prognosis and management decisions in regard to liver transplantation. As demonstrated, the percentage of liver necrosis in an adequate liver biopsy is a prognostic indicator of survival. More than 75% hepatic necrosis is associated with substantial transplant-free mortality, thus massive hepatic necrosis is worth considering as an indicator for liver transplantation. Importantly, survival is associated with etiology with the worst in those with hepatotropic viral hepatitis even after liver transplantation. Taken together, assessing the extent of hepatic necrosis and its underlying etiology can aid in screening candidates who may benefit most from liver transplantation, a lifesaving but expensive and high risk procedure. Early identification of transplant candidates is critical in optimizing the utilization of

resources.

COMMENTS

Background

Patients with fulminant hepatic failure often receive liver biopsies as part of the clinical work-up. In many instances, extensive hepatic necrosis is identified. The significance of extensive hepatic necrosis within a liver biopsy, as it relates to patient prognosis or treatment decisions, has not been well described.

Research frontiers

To our knowledge, no new studies addressing the significance of biopsy proven hepatic necrosis as it relates to patient prognosis have been published for over twenty years. The objective of our study was to identify what associations if any exist between hepatic necrosis, patient clinical characteristics, and survival.

Innovations and breakthroughs

This study shows trends suggesting that the extent of hepatic necrosis is associated with poorer patient survival. Further, we noticed a trend that patients who undergo liver transplantation tend to have a longer survival time. Additionally, higher extents of hepatic necrosis typically showed trends with clinical factors such as higher mean INR, and increased frequency of ascites or bacterial infections. While these trends all seemed to be present within our study, no statistical significance was identified, likely due to the small size of our study (in spite of us having the largest number of cases to date).

Applications

The trends evident within our study may provide future investigators with a starting point for their inquiries into how hepatic necrosis may play a role in patient management.

Terminology

Fulminant liver failure is clinically characterized by an abrupt onset of jaundice and liver dysfunction with subsequent development of encephalopathy and coagulopathy in patients with or without preexisting liver disease. Hepatic necrosis is defined as death of hepatocytes, which maybe single cell, multiple cells in piecemeal, focal, multifocal, submassive or massive. Submassive hepatic necrosis is defined as necrosis involving 26%-75% of the parenchymal volume, while massive necrosis involves more than 75%.

Peer-review

This paper evaluated if any association existed between the extent of hepatic necrosis and patient survival through observing the data resulted from 37 patients with fulminant liver failure, whose liver biopsy exhibited substantial necrosis. It was found that transplant-free survival was worse in patients with a higher extent of necrosis (40%, 71.4% and 100% in groups with necrosis of 76%-100%, 51%-75% and 26%-50%, respectively). So, the author concluded that adequate liver biopsy with more than 75% necrosis is associated with significant transplant-free mortality that is critical in predicting survival. This study has some scientific and clinic significances.

REFERENCES

- 1 **Shakil AO**, Kramer D, Mazariegos GV, Fung JJ, Rakela J. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. *Liver Transpl* 2000; **6**: 163-169 [PMID: 10719014 DOI: 10.1002/lt.500060218]
- 2 **Singhal A**, Vadlamudi S, Stokes K, Cassidy FP, Corn A, Shrago SS, Wright HI, Kohli V. Liver histology as predictor of outcome in patients with acute liver failure. *Transpl Int* 2012; **25**: 658-662 [PMID: 22487361 DOI: 10.1111/j.1432-2277.2012.01470.x]
- 3 **Sugawara K**, Nakayama N, Mochida S. Acute liver failure in Japan: definition, classification, and prediction of the outcome. *J Gastroenterol* 2012; **47**: 849-861 [PMID: 22825549 DOI: 10.1007/s00535-012-0624-x]
- 4 **Arroyo V**, Moreau R, Jalan R, Ginès P; EASL-CLIF Consortium CANONIC Study. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. *J Hepatol* 2015; **62**: S131-S143 [PMID: 25920082 DOI: 10.1016/j.jhep.2014.11.045]
- 5 **Wlodzimirow K**, Abu-Hanna A, Chamuleau RA. Acute-on-chronic liver failure - its definition remains unclear. *J Hepatol* 2013; **59**: 190-191 [PMID: 23462694 DOI: 10.1016/j.jhep.2013.02.011]
- 6 **Wlodzimirow KA**, Eslami S, Abu-Hanna A, Nieuwoudt M, Chamuleau RA. A systematic review on prognostic indicators of acute on chronic liver failure and their predictive value for mortality. *Liver Int* 2013; **33**: 40-52 [PMID: 22429562 DOI: 10.1111/j.1478-3231.2012.02790.x]
- 7 **Hanau C**, Munoz SJ, Rubin R. Histopathological heterogeneity in fulminant hepatic failure. *Hepatology* 1995; **21**: 345-351 [PMID: 7843704]
- 8 **Kessler WR**, Cummings OW, Eckert G, Chalasani N, Lumeng L, Kwo PY. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. *Clin Gastroenterol Hepatol* 2004; **2**: 625-631 [PMID: 15224287]
- 9 **Jalan R**, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, Arroyo V, Kamath PS. Acute-on chronic liver failure. *J Hepatol* 2012; **57**: 1336-1348 [PMID: 22750750 DOI: 10.1016/j.jhep.2012.06.026]
- 10 **Jalan R**, Gines P, Olson JC, Mookerjee RP, Moreau R, Garcia-Tsao G, Arroyo V, Kamath PS. Reply to: "Acute-on-chronic liver failure - its definition remains unclear". *J Hepatol* 2013; **59**: 191 [PMID: 23485518 DOI: 10.1016/j.jhep.2013.02.017]
- 11 **Jalan R**, Mookerjee RP. Acute-on-chronic liver failure: an early biopsy is essential? *Gut* 2010; **59**: 1455-1456 [PMID: 20947880 DOI: 10.1136/gut.2010.214627]
- 12 **O'Grady J**. Modern management of acute liver failure. *Clin Liver Dis* 2007; **11**: 291-303 [PMID: 17606208 DOI: 10.1016/j.cld.2007.04.011]
- 13 **Yamagishi Y**, Saito H, Tada S, Horie Y, Kato S, Ishii H, Shimojima N, Haga J, Shimazu M, Kitajima M, Hibi T. Value of computed tomography-derived estimated liver volume/standard liver volume ratio for predicting the prognosis of adult fulminant hepatic failure in Japan. *J Gastroenterol Hepatol* 2005; **20**: 1843-1849 [PMID: 16336442 DOI: 10.1111/j.1440-1746.2005.03949.x]
- 14 **Donaldson BW**, Gopinath R, Wanless IR, Phillips MJ, Cameron R, Roberts EA, Greig PD, Levy G, Blendis LM. The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators. *Hepatology* 1993; **18**: 1370-1376 [PMID: 8244261]
- 15 **Kirsch R**, Yap J, Roberts EA, Cutz E. Clinicopathologic spectrum of massive and submassive hepatic necrosis in infants and children. *Hum Pathol* 2009; **40**: 516-526 [PMID: 19121848 DOI: 10.1016/j.humpath.2008.07.018]
- 16 **Chan AC**, Fan ST, Lo CM, Liu CL, Chan SC, Ng KK, Yong BH, Chiu A, Lam BK. Liver transplantation for acute-on-chronic liver failure. *Hepatol Int* 2009; **3**: 571-581 [PMID: 19680733 DOI: 10.1007/s12072-009-9148-8]
- 17 **Duan BW**, Lu SC, Wang ML, Liu JN, Chi P, Lai W, Wu JS, Guo QL, Lin DD, Liu Y, Zeng DB, Li CY, Meng QH, Ding HG, Chen XY, Liao HY, Ma LQ, Chen Y, Zhang J, Xiang HP, Duan ZP, Li N. Liver transplantation in acute-on-chronic liver failure patients with high model for end-stage liver disease (MELD) scores: a single center experience of 100 consecutive cases. *J Surg Res* 2013; **183**: 936-943 [PMID: 23558257 DOI: 10.1016/j.jss.2013.03.008]
- 18 **Farmer DG**, Anselmo DM, Ghobrial RM, Yersiz H, McDiarmid SV, Cao C, Weaver M, Figueroa J, Khan K, Vargas J, Saab S, Han S, Durazo F, Goldstein L, Holt C, Busuttil RW. Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. *Ann Surg* 2003; **237**: 666-675; discussion 675-676 [PMID: 12724633 DOI: 10.1097/01.SLA.0000064365.54197.9E]
- 19 **Gotthardt D**, Riediger C, Weiss KH, Encke J, Schemmer P, Schmidt J, Sauer P. Fulminant hepatic failure: etiology and indications for liver transplantation. *Nephrol Dial Transplant* 2007; **22** Suppl 8: viii5-viii8 [PMID: 17890263 DOI: 10.1093/ndt/

gfm650]

- 20 **Ostapowicz G**, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin

JS, Blei AT, Samuel G, Reisch J, Lee WM. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. *Ann Intern Med* 2002; **137**: 947-954 [PMID: 12484709]

P- Reviewer: Gong ZJ **S- Editor:** Gong ZM **L- Editor:** A
E- Editor: Zhang FF





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327



9 771007 932045